Fresenius medical care executes on its strategic portfolio optimization program and announces key transactions

Divestments in 2023 are important milestones of the company's execution against its portfolio optimization which are part of the set strategic aspirations delivers on commitment to improve leverage ratio by allocating expected eur 0.5 billion proceeds from divestments to deleverage bad homburg, germany , jan. 8, 2024 /prnewswire/ -- fresenius medical care, the world's leading provider of products and services for individuals with renal diseases, today announced updates from transactions in 2023 as part of the company's ongoing portfolio optimization program. refocused on businesses and markets with the best strategic fit and greatest scale and sustainable profitable growth potential, fresenius medical care continues exiting unsustainable markets, divesting noncore and dilutive assets and prioritizing deleveraging as part of a disciplined and stringent approach to capital allocation.
FMS Ratings Summary
FMS Quant Ranking